sorafenib has been researched along with imiquimod in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (imiquimod) | Trials (imiquimod) | Recent Studies (post-2010) (imiquimod) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,264 | 284 | 1,963 |
| Protein | Taxonomy | sorafenib (IC50) | imiquimod (IC50) |
|---|---|---|---|
| Histamine H2 receptor | Homo sapiens (human) | 1.506 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 2.621 | |
| Adenosine receptor A2a | Homo sapiens (human) | 5.32 | |
| 7,8-dihydro-8-oxoguanine triphosphatase | Homo sapiens (human) | 0.646 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
1 other study(ies) available for sorafenib and imiquimod
| Article | Year |
|---|---|
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |